These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

476 related articles for article (PubMed ID: 23075850)

  • 1. Progressive degeneration of human neural stem cells caused by pathogenic LRRK2.
    Liu GH; Qu J; Suzuki K; Nivet E; Li M; Montserrat N; Yi F; Xu X; Ruiz S; Zhang W; Wagner U; Kim A; Ren B; Li Y; Goebl A; Kim J; Soligalla RD; Dubova I; Thompson J; Yates J; Esteban CR; Sancho-Martinez I; Izpisua Belmonte JC
    Nature; 2012 Nov; 491(7425):603-7. PubMed ID: 23075850
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Non-cell autonomous mechanism of Parkinson's disease pathology caused by G2019S LRRK2 mutation in Ashkenazi Jewish patient: Single cell analysis.
    Kim J; Daadi MM
    Brain Res; 2019 Nov; 1722():146342. PubMed ID: 31330122
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Parkinson's-disease-associated mutation LRRK2-G2019S alters dopaminergic differentiation dynamics via NR2F1.
    Walter J; Bolognin S; Poovathingal SK; Magni S; Gérard D; Antony PMA; Nickels SL; Salamanca L; Berger E; Smits LM; Grzyb K; Perfeito R; Hoel F; Qing X; Ohnmacht J; Bertacchi M; Jarazo J; Ignac T; Monzel AS; Gonzalez-Cano L; Krüger R; Sauter T; Studer M; de Almeida LP; Tronstad KJ; Sinkkonen L; Skupin A; Schwamborn JC
    Cell Rep; 2021 Oct; 37(3):109864. PubMed ID: 34686322
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neurite Aggregation and Calcium Dysfunction in iPSC-Derived Sensory Neurons with Parkinson's Disease-Related LRRK2 G2019S Mutation.
    Schwab AJ; Ebert AD
    Stem Cell Reports; 2015 Dec; 5(6):1039-1052. PubMed ID: 26651604
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In Vitro CRISPR/Cas9-Directed Gene Editing to Model LRRK2 G2019S Parkinson's Disease in Common Marmosets.
    Vermilyea SC; Babinski A; Tran N; To S; Guthrie S; Kluss JH; Schmidt JK; Wiepz GJ; Meyer MG; Murphy ME; Cookson MR; Emborg ME; Golos TG
    Sci Rep; 2020 Feb; 10(1):3447. PubMed ID: 32103062
    [TBL] [Abstract][Full Text] [Related]  

  • 6. LRRK2 mutations cause mitochondrial DNA damage in iPSC-derived neural cells from Parkinson's disease patients: reversal by gene correction.
    Sanders LH; Laganière J; Cooper O; Mak SK; Vu BJ; Huang YA; Paschon DE; Vangipuram M; Sundararajan R; Urnov FD; Langston JW; Gregory PD; Zhang HS; Greenamyre JT; Isacson O; Schüle B
    Neurobiol Dis; 2014 Feb; 62():381-6. PubMed ID: 24148854
    [TBL] [Abstract][Full Text] [Related]  

  • 7. LRRK2 kinase inhibitors reduce alpha-synuclein in human neuronal cell lines with the G2019S mutation.
    Zhao Y; Keshiya S; Perera G; Schramko L; Halliday GM; Dzamko N
    Neurobiol Dis; 2020 Oct; 144():105049. PubMed ID: 32800998
    [TBL] [Abstract][Full Text] [Related]  

  • 8. LRRK2 mutant iPSC-derived DA neurons demonstrate increased susceptibility to oxidative stress.
    Nguyen HN; Byers B; Cord B; Shcheglovitov A; Byrne J; Gujar P; Kee K; Schüle B; Dolmetsch RE; Langston W; Palmer TD; Pera RR
    Cell Stem Cell; 2011 Mar; 8(3):267-80. PubMed ID: 21362567
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The parkinson's disease-associated LRRK2 mutation R1441G inhibits neuronal differentiation of neural stem cells.
    Bahnassawy L; Nicklas S; Palm T; Menzl I; Birzele F; Gillardon F; Schwamborn JC
    Stem Cells Dev; 2013 Sep; 22(18):2487-96. PubMed ID: 23600457
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pathogenic LRRK2 mutations in nuclear ageing--a new organelle to study in Parkinson's disease.
    McKinley J; McCarthy A; Lynch T
    Mov Disord; 2013 Sep; 28(10):1344-5. PubMed ID: 24078329
    [No Abstract]   [Full Text] [Related]  

  • 11. Adenoviral-mediated expression of G2019S LRRK2 induces striatal pathology in a kinase-dependent manner in a rat model of Parkinson's disease.
    Tsika E; Nguyen AP; Dusonchet J; Colin P; Schneider BL; Moore DJ
    Neurobiol Dis; 2015 May; 77():49-61. PubMed ID: 25731749
    [TBL] [Abstract][Full Text] [Related]  

  • 12.
    Kim J; Daadi EW; Daadi ES; Oh T; Deleidi M; Daadi MM
    Cells; 2023 Oct; 12(21):. PubMed ID: 37947628
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impaired serine metabolism complements LRRK2-G2019S pathogenicity in PD patients.
    Nickels SL; Walter J; Bolognin S; Gérard D; Jaeger C; Qing X; Tisserand J; Jarazo J; Hemmer K; Harms A; Halder R; Lucarelli P; Berger E; Antony PMA; Glaab E; Hankemeier T; Klein C; Sauter T; Sinkkonen L; Schwamborn JC
    Parkinsonism Relat Disord; 2019 Oct; 67():48-55. PubMed ID: 31621607
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic correction of a LRRK2 mutation in human iPSCs links parkinsonian neurodegeneration to ERK-dependent changes in gene expression.
    Reinhardt P; Schmid B; Burbulla LF; Schöndorf DC; Wagner L; Glatza M; Höing S; Hargus G; Heck SA; Dhingra A; Wu G; Müller S; Brockmann K; Kluba T; Maisel M; Krüger R; Berg D; Tsytsyura Y; Thiel CS; Psathaki OE; Klingauf J; Kuhlmann T; Klewin M; Müller H; Gasser T; Schöler HR; Sterneckert J
    Cell Stem Cell; 2013 Mar; 12(3):354-67. PubMed ID: 23472874
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro genome editing rescues parkinsonism phenotypes in induced pluripotent stem cells-derived dopaminergic neurons carrying LRRK2 p.G2019S mutation.
    Chang KH; Huang CY; Ou-Yang CH; Ho CH; Lin HY; Hsu CL; Chen YT; Chou YC; Chen YJ; Chen Y; Lin JL; Wang JK; Lin PW; Lin YR; Lin MH; Tseng CK; Lin CH
    Stem Cell Res Ther; 2021 Sep; 12(1):508. PubMed ID: 34551822
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modeling Parkinson's disease using induced pluripotent stem cells.
    Byers B; Lee HL; Reijo Pera R
    Curr Neurol Neurosci Rep; 2012 Jun; 12(3):237-42. PubMed ID: 22538490
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of inducible leucine-rich repeat kinase 2 (LRRK2) cell lines for therapeutics development in Parkinson's disease.
    Huang L; Shimoji M; Wang J; Shah S; Kamila S; Biehl ER; Lim S; Chang A; Maguire-Zeiss KA; Su X; Federoff HJ
    Neurotherapeutics; 2013 Oct; 10(4):840-51. PubMed ID: 23963789
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Generation of gene-corrected iPSC line, KIOMi002-A, from Parkinson's disease patient iPSC with LRRK2 G2019S mutation using BAC-based homologous recombination.
    Lee SY; Chung SK
    Stem Cell Res; 2019 Dec; 41():101649. PubMed ID: 31731184
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dysregulated Wnt and NFAT signaling in a Parkinson's disease LRRK2 G2019S knock-in model.
    Wetzel A; Lei SH; Liu T; Hughes MP; Peng Y; McKay T; Waddington SN; Grannò S; Rahim AA; Harvey K
    Sci Rep; 2024 May; 14(1):12393. PubMed ID: 38811759
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A rat model of progressive nigral neurodegeneration induced by the Parkinson's disease-associated G2019S mutation in LRRK2.
    Dusonchet J; Kochubey O; Stafa K; Young SM; Zufferey R; Moore DJ; Schneider BL; Aebischer P
    J Neurosci; 2011 Jan; 31(3):907-12. PubMed ID: 21248115
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.